18f-bpapet.pptVIP

The Role of BPA-PET in Prediction of HN Cancer Treatment failure after BNCT Yu-Ming Liu, Yi-Wei Chen, Pin-Lun Li, Ko-Han Lin, Yu-Wen Hu, Ling-Wei Wang Div. of Radiation Oncology, Dept.of Oncology Taipei Veterans General Hospital Taiwan Mortality of Cancer in Taiwan (2010) Treatment of head neck cancer Surgery and radiation therapy with or without chemotherapy, but despite therapy, many cancers recur. Further treatment for recurrent H N cancer after multi-disciplined treatment is not uncommon Photon beams re-irradiation is not recommended because of high complication and low successful rate. LONG-TERM OUTCOME OF CONCURRENT CHEMOTHERAPYAND REIRRADIATION FOR RECURRENT AND SECOND PRIMARYHEAD-AND-NECK SQUAMOUS CELL CARCINOMA 115 previously irradiated patients without overt metastases Surgical resection, concurrent chemotherapy and re-irradiation The median lifetime radiation dose was 131 Gy. The median F/U for survival patients was 67.4 months (18.5–158.7). The median OS and PFS was 11 and 7 months (range, 0.2–158.7) The 3-year OS = 22 % PFS = 33 % Locoregional control = 51 % Freedom from distant metastasis = 61 % For recurrent and second primary head-and-neck cancer, trimodality therapy with OP, C/T and re-RT for a full second dose offers potential for long-term survival. Owing to the substantial toxicity and lack of an optimal regimen, re-irradiation of recurrent head-and-neck cancer should be limited to clinical trials. In theory, BNCT provides a means to selectively eradicate malignant cells and spare normal cells. To ensure success, a sufficient amount of 10B should be selectively delivered to the tumor and an adequate number of thermal neutrons should be absorbed in order to sustain a lethal 10B(n,α) 7Li capture reaction [Ono et al., IJROBP 34: 1081-1086, 1996]. For BPA-based BNCT, it is necessary to analyze the actual distribution of BPA